Array BioPharma, Inc. v. Eugia Pharma Specialities Limited et al
Plaintiff: Array BioPharma, Inc.
Defendant: Eugia Pharma Specialities Limited and Aurobindo Pharma USA, Inc.
Case Number: 1:2022cv01236
Filed: September 22, 2022
Court: US District Court for the District of Delaware
Presiding Judge: William C Bryson
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA)
Cause of Action: 35 U.S.C. ยง 271 Patent Infringement
Jury Demanded By: None
Docket Report

This docket was last retrieved on November 17, 2022. A more recent docket listing may be available from PACER.

Date Filed Document Text
November 17, 2022 Filing 14 MOTION for Pro Hac Vice Appearance of Attorney Gongjun ("Gary") Ji - filed by Aurobindo Pharma USA, Inc., Eugia Pharma Specialities Limited. (Neff, Carl)
November 17, 2022 Opinion or Order Filing 13 ORDER granting #12 Motion to Appear Pro Hac Vice Appearance of Attorney Gurpreet Singh Walia, M.D. Signed by Judge William C. Bryson on 11/17/2022. (srs)
November 17, 2022 Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Gurpreet Singh Walia, M.D. - filed by Aurobindo Pharma USA, Inc., Eugia Pharma Specialities Limited. (Neff, Carl)
November 17, 2022 Pro Hac Vice Attorney Gurpreet S. Walia for Aurobindo Pharma USA, Inc.,Gurpreet S. Walia for Eugia Pharma Specialities Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk)
November 15, 2022 Case Reassigned to Judge William C. Bryson of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (WCB) after the case number on all documents filed. (rjb)
October 14, 2022 Opinion or Order SO ORDERED re #11 STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the complaint to December 19, 2022 (Set/Reset Answer Deadlines: Aurobindo Pharma USA, Inc. answer due 12/19/2022; Eugia Pharma Specialities Limited answer due 12/19/2022). ORDERED by Judge Maryellen Noreika on 10/14/2022. (dlw)
October 13, 2022 Filing 11 STIPULATION TO EXTEND TIME to ANSWER complaint to December 19, 2022 - filed by Aurobindo Pharma USA, Inc., Eugia Pharma Specialities Limited. (Neff, Carl)
October 13, 2022 Filing 10 NOTICE of Appearance by Carl Douglas Neff on behalf of All Defendants (Neff, Carl)
September 30, 2022 Filing 9 AFFIDAVIT of Service for Summons, Complaint and related papers served on Eugia Pharma Specialities Limited on September 29, 2022, filed by Array BioPharma, Inc.. (Dellinger, Megan)
September 30, 2022 Filing 8 SUMMONS Returned Executed by Array BioPharma, Inc..Aurobindo Pharma USA, Inc. served on 9/29/2022, answer due 10/20/2022. (Dellinger, Megan)
September 28, 2022 Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb)
September 22, 2022 Filing 7 Amended Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: August 9, 2022. Date of Expiration of Patent: August 5, 2033.Thirty Month Stay Deadline: 12/27/2025. (Blumenfeld, Jack)
September 22, 2022 Filing 6 Summons Issued as to Aurobindo Pharma USA, Inc. on 9/22/2022; Eugia Pharma Specialities Limited on 9/22/2022. (Attachments: #1 Summons Issued)(mpb)
September 22, 2022 Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pfizer Inc. for Array BioPharma, Inc. filed by Array BioPharma, Inc.. (mpb)
September 22, 2022 Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,474,754 B2. (mpb)
September 22, 2022 Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/09/2022. Date of Expiration of Patent: 08/05/2033.Thirty Month Stay Deadline: 2/9/2025. (mpb)
September 22, 2022 Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb)
September 22, 2022 Filing 1 COMPLAINT filed against Aurobindo Pharma USA, Inc., Eugia Pharma Specialities Limited ( Filing fee $ 402, receipt number ADEDC-3964846.) - filed by Array BioPharma, Inc.. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(mpb)

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Delaware District Court's Electronic Court Filings (ECF) System

Search for this case: Array BioPharma, Inc. v. Eugia Pharma Specialities Limited et al
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Web [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Array BioPharma, Inc.
Represented By: Jack B. Blumenfeld
Represented By: Megan Elizabeth Dellinger
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Eugia Pharma Specialities Limited
Represented By: Carl Douglas Neff
Represented By: Gurpreet S. Walia
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Aurobindo Pharma USA, Inc.
Represented By: Carl Douglas Neff
Represented By: Gurpreet S. Walia
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?